The microbiome is the genetic material of all the microbes – bacteria, fungi, protozoa and viruses – that live on and inside the human body. The microbiome has essential beneficial functions relevant to supporting life and it is a fundamental component of human physiology. Changes in the microbiome can trigger changes in human cellular activities, resulting in disease or contribute to its progression but while the human microbiome is a hot topic of research the focus now includes microbes elsewhere are also important with recent studies showing that bacteria found on the skin might help to protect against cancer.
Nicola Davis a writer at The Guardian has just published an article ‘The human microbiome: why our microbes could be key to our health’ explains to readers the importance of microbes, how they interact with our body and why the microbiome has become such a hot topic for research.
SkinBioTherapeutics CEO Dr Catherine O’Neill commented on the article saying: “The level of interest in the microbiome is huge. People understand about the gut but now they’re beginning to see that the microbiome of other body systems is important also.”
SkinBioTherapeutics Plc (LON:SBTX) is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas Skin BioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept. The Skin Care Market is area of high growth currently worth $100+bn. For more information visit: http://www.skinbiotherapeutics.com
